www.bioss.com.cn
400-901-9800
sales@bioss.com.cn
techsupport@bioss.com.cn

Cat. Number:

bs-20135R-Gold

Quantity size:

100ul   15nm

Concentration:

0.4mg/ml  Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

GRIP2 are involved in the targeting of GluR-2 and GluR-3 to the synapse. GRIP1 and GRIP2 are widely expressed in brain, with the highest levels in the cerebral cortex, hippocampus and olfactory bulb. They are both enriched in synaptic plasma and postsynaptic density fractions. GRIP1 is expressed in early development before the expression of AMPA receptors, specifically postnatal days 8-10, while GRIP2 expression parallels that of AMPA receptors during later developmental stages. GRIP1 and GRIP2 may mediate the endocytotic rate of GluR-2 and GluR-3 in response to the phosphorylation of the receptors on Ser 880 by PKC, which is implicated in the induction of cerebellar long-term depression (LTD).

Also known as:

Glutamate receptor-interacting protein 2; GRIP-2; GRIP2_HUMAN; GRIP2; KIAA1719.

Specificity:

Storage:

0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles.

Application:

Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.